Business Description
Orum Therapeutics is a South Korean biopharmaceutical company, also operating in the United States, that develops new medicines targeting cancer and immune system disorders. Its pipeline includes treatments for conditions such as acute myeloid leukemia, lung cancer, and neuroendocrine tumors, with one candidate already in Phase I clinical trials and others in early-stage research. The company is also building a proprietary platform technology designed to attach protein-degrading agents to antibodies, allowing them to destroy harmful proteins more precisely. Founded in 2016 and based in Daejeon, South Korea, Orum Therapeutics is working to bring more targeted and effective therapies to patients with serious illnesses.
